Vertex Pharmaceuticals Inc (WBO:VRTX)
€ 410.1 +10.05 (+2.51%) Market Cap: 104.05 Bil Enterprise Value: 99.44 Bil PE Ratio: 27.78 PB Ratio: 6.15 GF Score: 90/100

Vertex Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 10, 2026 / 03:20PM GMT
Release Date Price: €381.1 (-0.79%)
Salveen Richter
Goldman Sachs International - Analyst

Good morning, everyone. Thank you so much for joining us. It's my pleasure to introduce Vertex Pharmaceuticals. And with us, we have Reshma Kewalramani, who's President and CEO of the company. Reshma, thank you for being here.

Reshma Kewalramani
Vertex Pharmaceuticals Inc - President, Chief Executive Officer, Director

You bet.

Questions & Answers

Salveen Richter
Goldman Sachs International - Analyst

Maybe just start here a high-level overview on the company. Help us understand where Vertex stands today in terms of your core cystic fibrosis and emerging pain and kidney autoimmune franchises, the key pipeline priorities and the outlook and strategy for the company as we head into the end of the decade.

Reshma Kewalramani
Vertex Pharmaceuticals Inc - President, Chief Executive Officer, Director

Sure thing. Sounds good. First of all, it's very nice to be here with you, Salveen. I know we're the last fireside

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot